EnBiotix uses breakthrough systems and synthetic biology platforms to revitalize existing antibiotics and develop new antibiotics and potentiators. Their robust clinical product pipeline addresses a wide range of acute and chronic infections, aiming to significantly impact patients' lives. EnBiotix was founded in 2012 and is headquartered in Cambridge, Massachusetts.